Continuous subcutaneous insulin infusion is very effective for the implementation of management of intensive diabetes to attain a normal level of glucose in the blood and for the betterment of lifestyles. When medical devices or drugs are concerned, people and the staff need to be aware of the disease and the nature of insulin pump therapy. Therefore, need and preparation for the management of the therapies are required. CSII should be implemented, followed, and prescribed by various professionals. There are various factors considered while selecting insulin pumps, which mainly include the durability of the pump, safety, training procedures provided by suppliers, easy usage, and application. Furthermore, insulin pump therapies are followed on a large scale and are generally recommended as they are very safe similar to the multiple-injection therapy.
COVID-19 scenario analysis:
- Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs, such as hydroxychloroquine, have witnessed a dramatic surge in demand for the management of COVID-19.
- Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs as many developed countries are short of these drugs. The pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19.
- Attributed to such factors, COVID-19 is expected to have a significant impact on the market.
Top impacting factors: Market scenario analysis, trends, drivers and impact analysis
Significant rise in the cases of diabetes patients along with awareness about the same and adoption of continuous subcutaneous insulin infusion (CSII) devices in the field of diabetes care due to its efficiency are the major factors that propel the growth of the continuous subcutaneous insulin infusion market.
Moreover, high expenses and investments in the healthcare sector specifically for diabetic patients and new policies being introduced for reimbursement that benefit the patients are factors that support the growth of the market.
Upgrades in technology, which encompass Internet of Things (IoT) and Artificial Intelligence (AI); and key manufactures working for the betterment of the devices and improving patient care help to drive the market growth. These devices are highly penetrated in the market in several regions.
Additionally, there have been advances in artificial intelligence and data analytics. These factors also affect the growth of the market positively.
New product launches and acquisitions to boost the market
On July 7th, 2017, Medtronic introduced a new device MiniMed 670G, the first closed-loop system that is hybrid. This introduced and helped in the growth of AI in the field of insulin infusion devices and was beneficial for patients and doctors as well. This new device helped to offer new opportunities for the continuous subcutaneous insulin infusion market. Additionally, on November 13th, 2018, Novo Nordisk India Pvt. Ltd. and Novo Nordisk Education Foundation (NNEF) introduced and ran an awareness program in India. On November 22nd, 2018, Nutrino, a startup in the nutrition data segment was acquired by Medtronic Plc after signing an agreement. On March 18th, 2019, Bigfoot Biomedical introduced its own closed-loop insulin system, which encompasses of Abbott Freestyle Libre glucose monitor.
Surge in usage in hospital applications
Hospitals, homecare, and laboratories are the major consumers of the continuous subcutaneous insulin infusion market. Amongst them, hospitals are the biggest end-users in the market. This is mainly due to the significant rise in hospitals and increase in investments in the hospital sector for the treatment of diabetes.
Furthermore, the home care sector is also increasing at a substantial rate. This is attributed to the rise in acceptance of insulin pumps and awareness of blood glucose level management. Additionally, increase in initiatives and policies by governments to create awareness for devices and the significant rise in patients' count who consume insulin on a daily basis also help in the growth of the market.
Key benefits of the report:
- This study presents the analytical depiction of the continuous subcutaneous insulin infusion market along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the continuous subcutaneous insulin infusion market share.
- The current market is quantitatively analyzed to highlight the continuous subcutaneous insulin infusion market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the continuous subcutaneous insulin infusion market.
- The report provides a detailed analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the continuous subcutaneous insulin infusion market research report:
- Which are the leading market players active in the market?
- What are the current trends that will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities of the market?
- What are the projections for the future that would help in taking further strategic steps?
Continuous Subcutaneous Insulin Infusion Market Report Highlights
| Aspects | Details |
 By Product Type |
|
 By Patient Type |
|
 By End User |
|
 By Region |
|
 Key Market Players | Tandem Diabetes Care, Ypsomed, F Hoffmann-La Roche, Insulet Corporation, Valeritas Inc., CeQur, Cellenovo, Medtronic Inc, Sooil Development |
Loading Table Of Content...
